Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Assertio Holdings, Inc. ASRT NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
31/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.38
-86.8%

Assertio Holdings, Inc. (ASRT) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $18.02. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is ASRT = $2 (-86.8% upside).

Valuation: ASRT trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25).

Financials: revenue is $119M, -8.5%/yr average growth. Net income is $30M (loss), growing at -115.3%/yr. Net profit margin is -24.9% (negative). Gross margin is 70.2% (-17.8 pp trend).

Balance sheet: total debt is $39M against $94M equity (Debt-to-Equity (D/E) ratio 0.42, conservative). Current ratio is 1.7 (strong liquidity). Debt-to-assets is 14.7%. Total assets: $267M.

Analyst outlook: 8 / 18 analysts rate ASRT as buy (44%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 43/100 (Partial), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 43/100 (Fail), Future 16/100 (Fail), Income 10/100 (Fail).

$2.38
▼ 86.79% Downside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Assertio Holdings, Inc., the average price target is $2.38, with a high forecast of $3.00, and a low forecast of $1.75.
Highest Price Target
$3.00
Average Price Target
$2.38
Lowest Price Target
$1.75

ASRT SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 43/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ASRT

~
VALUE Partial
43/100
ASRT trades at a trailing Price-to-Earnings (P/E) of -3.9 (S&P 500 average ~25). Trailing PEG 0.84. Analyst consensus target is $2, implying -88.9% from the current price $18. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ASRT: -8.5%/yr revenue is, -115.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ASRT: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet ASRT: Debt-to-Equity (D/E) ratio 0.42 (conservative), Current ratio is 1.7 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
43/100
ASRT: Gross margin is 70.2% (-17.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 8 / 18 analysts rate ASRT as buy (44%). Analyst consensus target is $2 (-88.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ASRT: Net profit margin is -24.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range7.65-20.45
Volume289.24K
Avg Volume (30D)105.31K
Market Cap$116.14M
Beta (1Y)0.43
Share Statistics
EPS (TTM)-4.74
Shares Outstanding$6.4M
IPO Date1997-12-03
Employees58
CEOMark L. Reisenauer
Financial Highlights & Ratios
Revenue (TTM)$118.71M
Gross Profit$83.33M
EBITDA$12.78M
Net Income$-29.51M
Operating Income$-21.54M
Total Cash$63.41M
Total Debt$39.12M
Net Debt$28.9M
Total Assets$266.97M
Price / Earnings (P/E)-3.8
Price / Sales (P/S)0.98
Analyst Forecast
1Y Price Target$2.38
Target High$3.00
Target Low$1.75
Upside-86.8%
Rating ConsensusHold
Analysts Covering18
Buy 44% Hold 50% Sell 6%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS04546C3043

Price Chart

Track all markets on TradingView
ASRT
Assertio Holdings, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Drug Manufacturers - Specialty & Generic
7.65 52WK RANGE 20.45

People Also View

ITCI
ITCI
Intra-Cellular Therapies, Inc.
$131.87
+0.00%
 NBIX
NBIX
Neurocrine Biosciences, Inc.
$130.81
+3.55%
 CTLT
CTLT
Catalent, Inc.
$63.48
+0.00%
 RDY
RDY
Dr. Reddy's Laboratories Limited
$13.13
-1.06%
 ALKS
ALKS
Alkermes plc
$33.87
+0.36%
 AMRX
AMRX
Amneal Pharmaceuticals, Inc.
$13.12
+2.26%
 DCPH
DCPH
Deciphera Pharmaceuticals, Inc.
$25.59
+0.08%
 ANIP
ANIP
ANI Pharmaceuticals, Inc.
$78.29
-0.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message